Clinical Trials

Breast Cancer
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Gynecological Cancers
A Phase II Evaluation of Afatinib
- Ages18 years and younger
- GenderFemale only
Lung Cancer
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Breast Cancer
A Safety Study of SGN-LIV1A in Breast Cancer Patients
- Ages18 years and older
- GenderFemale only
Breast Cancer
Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS: A Phase III Prospective Randomized Trial
Breast Cancer
I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)
Colorectal Cancer, Sarcoma Cancers, Brain and Other Nervous System Cancers, Breast Cancer, Gynecological Cancers, Stomach and Esophagus, Other Cancers, Lymphoma, Kidney Cancer, Head and Neck Cancers, Liver Cancer, Lung Cancer, Leukemia, Melanoma, Thyroid and Other Endocrine Cancers, Bladder Cancer, Pancreatic Cancer, Prostate Cancer
NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
- Ages18 years and older
- GenderBoth
Breast Cancer
Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive Breast Cancer
Breast Cancer
Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab + Neoantigen Vaccine vs. Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab in Patients With Metastatic Triple Negative Breast Cancer
Colorectal Cancer
S0820, Adenoma and Second Primary Prevention Trial (PACES)S0820, Adenoma and Second Primary Prevention Trial (PACES)
- Ages18 years and older
- GenderBoth